The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.

Inclusion Criteria:

• Patient age ≥ 18 years and ≤ 75 years；
• Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia；
• Recurrent disease with obvious symptoms prior to enrollment;
• Failure to respond to or intolerance of at least one antiarrhythmic drug;
• Fully understand the treatment plan, voluntarily sign the informed consent form, and agree to undergo the examinations, procedures and follow-up as required by the protocol.

Exclusion Criteria:

• Left ventricular ejection fraction (LVEF) ≤ 40%
• History of ventricular flutter or ventricular fibrillation
• Diagnosis of long QT syndrome or arrhythmogenic cardiomyopathy
• Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease
• Previous atrial septal repair or atrial myxoma
• Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.)
• NYHA functional class Ⅲ-Ⅳ
• Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, transient ischemic attack)
• Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision)
• Patients with acute or severe systemic infection
• Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial
• Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders
• Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment
• Patients with other conditions deemed inappropriate for participation in this trial by the investigator.

This trial protocol is available in Chinese only and has not yet been translated into English.